Skip to content
Screener

Immunovant, Inc. IMVT United States — United States – Federal

Similar metrics at other companies

Reynolds Consumer Products Inc. logo
REYNUnited States — Federal
$16.25M-30.1%
Alset Inc. logo
AEIMaryland State — Current Federal Tax Expense Benefit
$92.96K+152%
Reynolds Consumer Products Inc. logo
REYNUnited States — State
$2.75M-15.4%
Astronics logo
ATROUnited States — Sales
$153.77M+3.6%
GTL
GTLSUnited States — Sales
$449.33M+8.3%
Olin logo
OLNUnited States — Sales
$1.15B+0.8%

Other financials

Income statement

See full
Net income-$147.9M-38.9%
EPS (diluted)-$0.73-15.9%

Balance sheet

See full
Cash & equivalents$902.1M+26.4%
Total debt$72.0K-26.5%
Total equity$852.6M+20.5%
Total assets$957.0M+23.3%

Cash flow

See full
Operating cash flow-$95.1M+14.1%
CapEx$8.0K-96.0%
Free cash flow-$95.1M+14.2%

Valuation

See full
Market cap$8.21B+201%
Enterprise value$7.31B+89.7%

Returns & leverage

See full
Return on equity-64.8%+2.5pp
Debt / equity0.0×
Current ratio9.1×-2.1×

Where this comes from

Reported directly by Immunovant, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CurrentFederalTaxExpenseBenefit.

The source filing: Immunovant, Inc.’s 10-K, filed May 20, 2026.

Filed
May 20, 2026, 7:28 AM EDT
Fiscal year
FY2026
Accession
0001764013-26-000064
Line itemYears Ended March 31, 2026Years Ended March 31, 2025Years Ended March 31, 2024
United Kingdom(55)
Total loss before income taxes$(505,391)$(412,949)$(258,769)
Current taxes
United States – Federal$880$562
United States – State215115
Total current tax expense215891567
Deferred tax expense
Total provision for income taxes$215$891$567

Item 8. Financial Statements and Supplementary Data

FAQ

What is Immunovant, Inc.'s united states — united states – federal?
Immunovant, Inc. (IMVT) reported united states — united states – federal of $0 in Q1 2026.
How has Immunovant, Inc.'s united states — united states – federal changed year-over-year?
Immunovant, Inc.'s united states — united states – federal decreased by 100.0% year-over-year, from $220K to $0.
What is the long-term trend for Immunovant, Inc.'s united states — united states – federal?
Over 4 years (2022 to 2026), Immunovant, Inc.'s united states — united states – federal has grown at a -100.0% compound annual growth rate (CAGR), from -$85K to $0.
What does united states — united states – federal mean?
Refers to the portion of income tax expense or benefit attributable to the United States federal government for the domestic segment. This reflects the tax obligations or credits incurred at the national level based on domestic earnings. It is essential for understanding the impact of federal tax policy on the company's domestic financial results.

Ask your AI about Immunovant, Inc.'s united states — united states – federal.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude